103906-66-7

Basic information

• Product Name: 4-CHLORO-1-(2-CHLOROPHENYL)-1-OXOBUTANE
• Synonyms: 4-CHLORO-1-(2-CHLOROPHENYL)-1-OXOBUTANE
• CAS NO: 103906-66-7
• Molecular Formula: C₁₀H₁₀Cl₂O
• Molecular Weight: 217.09
• Mol File: 103906-66-7.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 296.059°C at 760 mmHg
• Flash Point: 123.874°C
• Appearance: /
• Density: 1.224g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.536
• CAS DataBase Reference: 4-CHLORO-1-(2-CHLOROPHENYL)-1-OXOBUTANE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-1-(2-CHLOROPHENYL)-1-OXOBUTANE(103906-66-7)
• EPA Substance Registry System: 4-CHLORO-1-(2-CHLOROPHENYL)-1-OXOBUTANE(103906-66-7)

Safety Data

• Hazardous Substances Data: 103906-66-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H10Cl2O/c11-7-3-6-10(13)8-4-1-2-5-9(8)12/h1-2,4-5H,3,6-7H2

Upstream product

• 77390-23-9 3-(2-chlorobenzoyl)-2,3,4,5-tetrahydrofuran-2-one 

Downstream Products

• 566198-06-9 3-(2-chlorophenyl)-5,6-dihydro-4H-1,2-oxazine 
• 566198-05-8 4-chloro-1-(2-chlorophenyl)butan-1-one oxime 

Relevant articles and documents

Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor

Haloperidol is a typical antipsychotic drug (APD) associated with an increased risk of extrapyramidal side effects (EPSs) and hyperprolactinemia relative to atypical APDs such as clozapine. Both drugs are dopamine D2 receptor (D2R) antagonists, with contrasting kinetic profiles. Haloperidol displays fast association/slow dissociation at the D2R, whereas clozapine exhibits relatively slow association/fast dissociation. Recently, we have provided evidence that slow dissociation from the D2R predicts hyperprolactinemia, whereas fast association predicts EPS. Unfortunately, clozapine can cause severe side effects independent of its D2R action. Our results suggest an optimal kinetic profile for D2R antagonist APDs that avoids EPS. To begin exploring this hypothesis, we conducted a structure-kinetic relationship study of haloperidol and revealed that subtle structural modifications dramatically change binding kinetic rate constants, affording compounds with a clozapine-like kinetic profile. Thus, optimization of these kinetic parameters may allow development of novel APDs based on the haloperidol scaffold with improved side-effect profiles.